CAMBRIDGE, Mass.--(BUSINESS WIRE)--Aug 1, 2018--Sage Therapeutics (NASDAQ: SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, today announced that the Company will present at the Canaccord 38th Annual Growth Conference on Wednesday, August 8, 2018 at 11:00 A.M. ET in Boston, MA.

A live webcast of the presentation can be accessed on the investor page of Sage's website at investor.sagerx.com. A replay of the webcast will also be archived for up to 30 days on Sage's website following the conference.

About Sage Therapeutics

Sage Therapeutics is a clinical-stage biopharmaceutical company committed to developing novel medicines to transform the lives of patients with life-altering CNS disorders. Sage has a portfolio of novel product candidates targeting critical CNS receptor systems, GABA A and NMDA. Sage's lead program, a proprietary IV formulation of brexanolone (SAGE-547), has completed Phase 3 clinical development for postpartum depression and a New Drug Application is currently under review with the U.S. Food and Drug Administration. Sage is developing its next generation modulators, including SAGE-217 and SAGE-718, in various CNS disorders. For more information, please visit www.sagerx.com.

View source version on businesswire.com:https://www.businesswire.com/news/home/20180801005058/en/

CONTACT: Sage Therapeutics

Investor Contact:

Paul Cox, 617-299-8377

paul.cox@sagerx.com

or

Media Contact:

Maureen L. Suda, 585-355-1134

maureen.suda@sagerx.com

KEYWORD: UNITED STATES NORTH AMERICA MASSACHUSETTS

INDUSTRY KEYWORD: HEALTH BIOTECHNOLOGY CLINICAL TRIALS PHARMACEUTICAL GENERAL HEALTH

SOURCE: Sage Therapeutics

Copyright Business Wire 2018.

PUB: 08/01/2018 06:30 AM/DISC: 08/01/2018 06:31 AM

http://www.businesswire.com/news/home/20180801005058/en